Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus ZINACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX IN PLASTIC CONTAINER versus ZINACEF.
KEFUROX IN PLASTIC CONTAINER vs ZINACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
Cefuroxime, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
750 mg IV/IM every 8 hours; for severe infections: 1.5 g IV every 8 hours; for life-threatening infections: 1.5 g IV every 6 hours
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Terminal elimination half-life: 1.5-2 hours in adults with normal renal function; prolonged to 2.5-3.5 hours in elderly and up to 48 hours in end-stage renal disease.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Renal: 80-95% unchanged via glomerular filtration and tubular secretion; biliary: 5-10% excreted in feces; fecal: negligible.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic